Codexis (CDXS) Return on Capital Employed (2011 - 2026)
Codexis (CDXS) posted quarterly Return on Capital Employed of 23.68% for Q1 2026, up 3318.0% year-over-year from 0.69% in Q1 2025, and up 37.28% quarter-over-quarter from 37.75% in Q4 2025.
Codexis (CDXS) Return on Capital Employed (2011 - 2026) Analysis & Trends
Codexis' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 23.68% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 3318.0% year-over-year to 23.68%; the TTM figure through Mar 2026 stood at 23.68% (up 3318.0% YoY), while the FY2025 annual figure was 33.91%, up 1521.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 23.68%, up from 37.75% in the prior quarter.
- The five-year high for Return on Capital Employed was 9.78% in Q2 2022, with the low at 62.06% in Q4 2023.
- The 5-year median for Return on Capital Employed is 46.83% (2024), against an average of 38.68%.
- The sharpest annual moves came in 2023 and 2026: Return on Capital Employed plunged 4406 bps in 2023, then surged 3318 bps in 2026.
- Codexis' Return on Capital Employed stood at 18.0% in 2022, then slumped by 245 bps to 62.06% in 2023, then rose by 25 bps to 46.83% in 2024, then advanced by 19 bps to 37.75% in 2025, then jumped by 37 bps to 23.68% in 2026.
- Business Quant data shows CDXS's Return on Capital Employed at 23.68% in Q1 2026, 37.75% in Q4 2025, and 52.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Codexis | 152.06 Mn | 97.14 Mn | 11.40 Mn | -27.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.33% |
| Mar 31, 2026 | -23.68% |
| Dec 31, 2025 | -37.75% |
| Sep 30, 2025 | -52.95% |
| Jun 30, 2025 | -48.38% |
| Mar 31, 2025 | -56.85% |
| Dec 31, 2024 | -46.83% |
| Sep 30, 2024 | -48.49% |
| Jun 30, 2024 | -60.23% |
| Mar 31, 2024 | -49.39% |
| Dec 31, 2023 | -62.06% |
| Sep 30, 2023 | -57.39% |
| Jun 30, 2023 | -34.06% |
| Mar 31, 2023 | -25.60% |
| Dec 31, 2022 | -18.00% |
| Sep 30, 2022 | -15.75% |
| Jun 30, 2022 | -9.78% |
| Mar 31, 2022 | -10.38% |
| Dec 31, 2021 | -11.15% |
| Sep 30, 2021 | -8.71% |